U.S. Markets closed

Mesoblast Limited (MSB.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
1.9400+0.0650 (+3.47%)
As of 10:29AM AEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8750
Open1.9050
Bid1.9350 x 1092600
Ask1.9400 x 5097500
Day's Range1.9000 - 1.9450
52 Week Range1.7000 - 5.7000
Volume471,040
Avg. Volume2,394,959
Market Cap1.256B
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-0.2520
Earnings DateAug 25, 2021 - Aug 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.87
  • Appendix 4C Quarterly Activity Report
    GlobeNewswire

    Appendix 4C Quarterly Activity Report

    Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2021NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the fourth quarter ended June 30, 2021. “During the quarter we made significant progress in both regulatory and clinical outcomes for our lead product candidate

  • Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
    Benzinga

    Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial

    Mesoblast Limited (NASDAQ: MESO) has announced the presentation of 90-day survival outcomes from the remestemcel-L trial in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). The data were presented at the International Society for Cell & Gene Therapy Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses. The results showed that two doses of remestemcel-L at days 3-5 conferred durable survival benefit

  • Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
    GlobeNewswire

    Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases

    NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at an invited presentation on July 17 to the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series on Cel